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ABSTRACT: eaRly-start ExerciSe training afTer acute hemo-
dynAmic decompensation in patients with chRonic hearT
failure (RE-START). A. Mezzani, F. Cacciatore, R. Catanzaro,
A. Gualco, D. Guzzetti, D. Leosco, M. Monelli, F. Tarro Genta,
P. Totaro, E. Traversi, E. Zanelli, P. Giannuzzi.
RE-START is a multicenter, randomized, prospec-
tive, open, controlled trial aiming to evaluate the feasi-
bility and the short- and medium-term effects of an early-
start AET program on functional capacity, symptoms and
neurohormonal activation in chronic heart failure (CHF)
patients with recent acute hemodynamic decompensation.
Study endpoints will be: 1) safety of and compliance to
AET; 2) effects of AET on i) functional capacity, ii) pa-
tient-reported symptoms and iii) AET-induced changes in
beta-adrenergic receptor signaling and circulating angio-
genetic and inflammatory markers. Two-hundred pa-
tients, randomized 1:1 to training (TR) or control (C), will
be enrolled. Inclusion criteria: 1) history of systolic CHF
for at least 6 months, with ongoing acute decompensation
with need of intravenous diuretic and/or vasodilator
therapy; 2) proBNP >1000 pg/ml at admission. Exclusion
criteria: 1) ongoing cardiogenic shock; 2) need of intra-
venous inotropic therapy; 3) creatinine >2.5 mg/dl at ad-
mission. After a 72-hour run-in period, TR will undergo
the following 12-day early-start AET protocol: days 1-2:
active/passive mobilization (2 sessions/day, each 30 min-
utes duration); days 3-4: as days 1-2 + unloaded bedside
cycle ergometer (3 sessions/day, each 5-10 minutes dura-
tion); days 5-8: as days 1-2 + unloaded bedside cycle er-
gometer (3 sessions/day, each 15-20 minutes duration);
days 9-12: as days 1-2 + bedside cycle ergometer at 10-20
W (3 sessions/day, each 15-20 minutes duration). During
the same period, C will undergo the same activity protocol
as in days 1-2 for TR. All patients will undergo a 6-
minWT at day 1, 6, 12 and 30 and echocardiogram, pa-
tient-reported symptoms on 7-point Likert scale and mea-
surement of lymphocyte G protein coupled receptor ki-
nase, VEGF, angiopoietin, TNF alfa, IL-1, IL-6 and eNOS
levels at day 1, 12 and 30.
Key words: chronic heart failure, hemodynamic decom-
pensation, physical training, functional capacity, neurohu-
moral activation.
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Introduction
Chronic heart failure (CHF) is a disabling syn-
drome that affects close to 7 million Europeans and
5 million North Americans. Hospitalization rates
have progressively increased over time, and the an-
nual incidence reaches 2% to 3% in patients older
than 85 years. In Italy, there were nearly 185000
hospital admissions for decompensated CHF in
2001, and CHF costs represent 1.4% of yearly health
care expenditures. An ideal agent for treating
acutely decompensated CHF patients should reduce
left ventricular filling pressures, improve symptoms
and renal function, preserve myocardial tissue, re-
duce neurohormonal levels, and not be arrhythmic
or induce symptomatic hypotension (1). Interest-
ingly, aerobic exercise training (AET) does have
several such characteristics. AET is a well-estab-
lished non-pharmacologic treatment of stable CHF
patients, which has been shown to determine favor-
able central and peripheral adaptations, reducing the
neurohormonal activation typical of the CHF patho-
physiological picture and hence improving func-
tional capacity and quality of life (2-4). The efficacy
of AET in CHF has been evaluated in patients in
stable New York Heart Association class I to III, but
no data at all are available in patients with recent
acute decompensation, i.e. a severely symptomatic
population with poor functional capacity, maximal
neurohormonal activation and bad prognosis. In this
regard, preliminary data in normal subjects show an
early increase of flow-mediated vasodilation (i.e.
one of the main determinants of total peripheral re-
sistance and left ventricular afterload) to AET,
which becomes evident and statistically significant
after three days of training (5). Similarly, a favorable
adaptation of sympatho-vagal balance (i.e. an in-
creased parasympathetic tone) as early as one day
after AET start has been demonstrated (6). 
Objective
RE-START aims at evaluating the feasibility
and the short- and medium-term effects of an early-
start AET program on functional capacity, neuro-
hormonal activation and quality of life in CHF pa-
tients with recent acute decompensation, a popula-
tion usually excluded by formal training programs.
Our working hypothesis is that AET should impact
the pathophysiology of recently decompensated
CHF, by favorably modulating the increase of total
peripheral resistance and the sympathetic overacti-
vation typical of this syndrome. In addition, AET
should induce a more rapid functional recovery of
patients after a period of obligatory bed rest due to
hemodynamic instability. Overall, these effects are
expected to exert a favorable clinical effect, possibly
reducing the short- and medium-term rate of rehos-
pitalizations of trained patients. 
Methods
Study type and endpoints
RE-START is a multicenter, randomized,
prospective, open and controlled trial. All Cardiac
Rehabilitation Divisions of the Salvatore Maugeri
Foundation, IRCCS, will participate in the trial. The
primary endpoints evaluated in the study will be: 1)
safety of and compliance to AET; 2) effects of AET
on i) functional capacity, evaluated as distance
walked at 6-min walking test (6-minWT) and ii) pa-
tient-reported symptoms, evaluated by the 7-point
Likert scale. Secondary outcome will be evaluation
of AET-induced changes in beta-adrenergic receptor
signaling and circulating angiogenetic and inflam-
matory markers. 
Study population
Statistical power calculation for repeated-mea-
sures ANOVA indicates that, assuming a 40% in-
crease of distance walked at 6-minWT in the
training group after early-start AET, 200 patients,
randomized 1:1 to training or control, will have to
be enrolled in the study to detect a significant time x
group interaction (power = 0.80, alfa = 0.05). 
Inclusion criteria will be as follows: 1) history of
CHF for at least 6 months, with ongoing acute de-
compensation defined as onset or worsening of heart
failure signs and/or symptoms during the previous
15 days with need of intravenous diuretic and/or va-
sodilator therapy; 2) age >18 years; 3) left ventric-
ular ejection fraction <40%; 4) proBNP >1000
pg/ml at admission. Exclusion criteria will be: 1) on-
going cardiogenic shock; 2) need of intravenous in-
otropic therapy; 3) acute coronary syndrome during
the preceding 3 months; 4) clinical and/or instru-
mental evidence of myocardial ischemia and/or life-
threatening arrhythmias; 5) previous cardiac valve
surgery; 6) creatinine >2.5 mg/dl at admission; 7)
severe comorbidities limiting functional capacity.
Intervention
All patients with CHF admitted in the partici-
pating Centers for acute hemodynamic decompensa-
tion will be screened for recruitment in the study.
After 72-hour of pharmacologic treatment, eligible
patients will be randomized 1:1 to training (TR) or
control (C). TR will undergo the following 12-day
early-start AET protocol: days 1-2: active/passive
mobilization (2 sessions/day, each 30 minutes dura-
tion); days 3-4: as days 1-2 + unloaded bedside
cycle ergometer (3 sessions/day, each 5-10 minutes
duration); days 5-8: as days 1-2 + unloaded bedside
cycle ergometer (3 sessions/day, each 15-20 minutes
duration); days 9-12: as days 1-2 + bedside cycle er-
gometer at 10-20 W (3 sessions/day, each 15-20
minutes duration). During the same period, C will
undergo only the same activity protocol as in days 1-
2 for TR. In addition, when possible according to
their clinical conditions, both TR and C will undergo
one assisted ambulation session of 15-20 minutes
per day. 
As AET has never been tested to date in re-
cently decompensated CHF patients, assessment of
treatment feasibility (with a special attention to
safety) is a primary outcome of the study. In any
case, as the functional capacity of recruited patients
is expected to be severely reduced, a low-intensity
training stimulus should be sufficient to obtain a
training effect, which should reduce to the min-
imum possible exercise-related risks. Short-term
safety of and compliance to the early-start AET
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program will be evaluated by monitoring adverse
events, number of training sessions performed, total
training time and percent of prescribed sessions
time carried out. All patients will undergo a 6-
minWT at day 1, 6, 12 and 30. A standardized pro-
cedure will be followed, with walks taking place at
approximately the same time of the day, at least 2
hours after a meal. Patients will be asked to walk
from one end to the other of a 20 m walking track,
covering as much ground as possible in 6 minutes.
Patients will be allowed to rest whenever required
and to stop if angina, dyspnea, or musculoskeletal
pain occur or in case of attainment of hemoglobin
oxygen saturation levels <85%. If a patient will not
be able to walk, a distance equal to 0 meters will be
recorded. In addition, the following evaluations will
be carried out at day 1, 12 and 30: 1) echocardio-
gram; 2) patient-reported symptoms on 7-point
Likert scale; 3) measurement of lymphocyte G pro-
tein coupled receptor kinase, VEGF, angiopoietin,
TNF alfa, IL-1, IL-6 and eNOS levels. A telephonic
follow-up aiming at recording clinical events pos-
sibly occurred after the 30-day evaluation will be
carried out at 3 and 6 months after randomization.
Significance and innovation
This study can provide information about both
feasibility and efficacy of AET as a new and low-
cost tool for the management of recently decompen-
sated CHF patients. If proven feasible end efficient
early after acute decompensation of CHF, i.e. during
a period never taken into consideration to date for
formal exercise training in this patient population,
AET may enter the therapeutic armamentarium of
recently decompensated CHF beside traditional
pharmacologic treatments.
Riassunto
RE-START è uno studio multicentrico, rando-
mizzato, prospettico, in aperto e controllato, che
mira a valutare la fattibilità e gli effetti a breve e
medio termine di un programma di training aero-
bico (TA) ad avvio precoce su capacità funzionale,
sintomi e attivazione neuro-ormonale nei pazienti
con scompenso cardiaco cronico (SCC) e recente in-
stabilizzazione emodinamica. Gli endpoint primari
dello studio saranno: 1) sicurezza del TA e com-
pliance ad esso da parte dei pazienti; 2) effetti del
TA su capacità funzionale, valutata come distanza
percorsa al walking test di 6 minuti e sintomi, valu-
tati mediante 7-point Likert scale. Endpoint secon-
dario sarà la valutazione delle modificazioni indotte
dal TA sul signaling beta-recettoriale e sui livelli di
marker angiogenetici e infiammatori circolanti. Sa-
ranno arruolati 200 pazienti, con storia di scom-
penso sistolico da almeno 6 mesi e instabilizzazione
acuta in atto (definita come esordio o peggiora-
mento di segni e/o sintomi di scompenso cardiaco
durante i 15 giorni precedenti), con necessità di te-
rapia diuretica e/o vasodilatatrice e.v. Principali
criteri d’esclusione saranno: 1) shock cardiogeno in
atto; 2) necessità di terapia con inotropi e.v.; 3)
creatinina >2.5 mg/dl; 4) presenza di severa/e co-
morbidità limitante/i la capacità funzionale del pa-
ziente. Dopo 72 ore di trattamento farmacologico, i
pazienti eleggibili saranno randomizzati 1:1 a TA o
controllo (C). Il gruppo TA sarà sottoposto a un pro-
tocollo di training della durata di 12 giorni, che pre-
vede sedute di cicloergometro da camera a carichi
crescenti e di mobilizzazione assistita. Il gruppo C
eseguirà solo mobilizzazione assistita. Tutti i pa-
zienti saranno sottoposti a walking test di 6 minuti
al giorno 1, 6, 12 e 30. Inoltre, le seguenti valuta-
zioni saranno eseguite ai giorni 1, 12 e 30: ecocar-
diogramma; sintomi riportati dal paziente secondo
la 7-point Likert scale; livelli ematici di lymphocyte
G protein-coupled receptor kinase-2, VEGF, angio-
poietina, TNF-alfa, IL-1 e IL-6.
Lo studio fornirà informazioni utili per valutare
adeguatamente la sicurezza del TA ad avvio precoce
e i suoi effetti a breve e medio termine su capacità
lavorativa e sintomi nei pazienti con SCC recente-
mente instabilizzato. Inoltre, i risultati di questo
studio permetteranno di valutare gli effetti del TA ad
avvio precoce su signaling beta-recettoriale e livelli
di marker angiogenetici e infiammatori circolanti,
ponendo le basi razionali per futuri studi sull’argo-
mento dotati di adeguata potenza statistica.
Parole chiave: scompenso cardiaco, scompenso
emodinamico, training fisico, attivazione neu-
roumorale
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